November 24, 2007
Diabetes and Related Eye Disorders
Diabetic Retinopathy is the leading cause of vision loss among working adults in the US. The good news is that severe ocular changes can be avoided by good blood glucose maintenance, and timely evaluations and treatments. The incidence of Diabetic Retinopathy is related to the length of time that an individual has Diabetes. For example, some one who has the disease is unlikely to have retinal changes if they were diagnosed less then 5 years ago. After 10 years that number jumps to about 71% and may go higher if the blood sugar is not well controlled. People with Diabetes more then 20 years run a 95% chance of having either Diabetic Retinopathy or Diabetic Macular Edema.
Diabetic Retinopathy is manifested by leaking blood vessels resulting in retinal hemorrhages, and the release of proteins into the retinal tissue. This causes death to the underlying areas if left untreated and Cotton Wool spots are the end product. These are white dead spots in the retina. The damage is permanent, and thus early treatment is always recommended to try and prevent these damaging changes. Diabetic Macular Edema (DME) is when the central most area of the retina that houses the highest concentration of neuroreceptors has an accumulation of fluid. This lifts up the retina, and decreases vision. Over 14% of mild to moderate diabetics will develop DME after 10 years of having Diabetes, and the incidence increases with the severity of the disease.
Diabetic changes appear to be related to a chemical called Vascular Endothelial Growth Factor (VEGF). This chemical is secreted into certain tissues when there is oxygen deprivation, death or damage to that area. VEGF results in increased vascular permeability that causes the hemorrhages to occur. VEGF results in the neovascular blood vessel growth in the Iris, retina and near the optic nerve if untreated. Accurate diagnosis of these changes requires the use of both Fluorescein Angiography, and the Optical Coherence Tomography (OCT). The OCT actually shows a picture of the retinal area in question, and both edema and blood vessel changes can be visualized.
Current treatment options include Laser Therapy called Photo coagulation which seals the leaking blood vessels, and slows the visual deterioration. Frequently, multiple applications are needed. These laser burns result in scars in the affected areas, and there is loss of all vision in those parts of the retina. When there is blood in the jelly of the eye, the Vitreous, a Vitrectomy may be required. This involves removing the jelly and replacing it with a clear fluid. During this procedure, retinal scar tissue can also be extracted clearing the underlying retinal tissue. Pharmacological treatments are very limited at this time, but there are several under investigation.
Triamcinolone which is a steroid, has been injected into the eye to reduce the Macular Edema with some success. The problem with this steroid is that it has been found to cause both cataracts and glaucoma. Macugen is a VEGF inhibitor and thus removes the catalyst that causes the diabetic changes in the first place. A new development is the use of Avastin which is a strong VEGF inhibitor which has been approved for the treatment of colorectal cancer. It has been shown to dramatically help in Diabetic Retinopathy. Lucentis is a selective form of Avastin and is the strongest of all the drugs to help with Diabetic Retinopathy. The cost of a Lucentis injection is about 10 times that of the Avastin so Avastin is preferred although Lucentis will surpass it if proven to be a better treatment. They are both made by the same company.
In short, Diabetes is a disease that over time will destroy ones’ body. The best treatment is to control the blood sugar every day as best as possible. Failure to do so will result in severe consequences that are irreversible.
Tech Tags: Diabetic Retinopathy diabetes Macular Edema Vascular Endothelial Growth Factor VEGF Fluorescein Angiography Laser Therapy Photo coagulation Vitreous Vitrectomy Triamcinolone Macugen Avastin Lucentis




